SGN-00101

· Nventa Biopharmaceuticals Corporation

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for SGN-00101, covering 2007-06-27 to 2018-05-21. Get the full timeline:

Most recent: Clinical Trial Update: SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia [Phase 2]